Inhibitex to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City on Tuesday, November 17, 2009 at 1:40 p.m. Eastern Time.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company’s pipeline includes FV-100, its clinical-stage nucleoside analogue in Phase II development for the treatment of herpes zoster (shingles), as well as INX-189, an HCV nucleotide polymerase inhibitor in preclinical development. Inhibitex has also licensed the use of its proprietary MSCRAMM® protein technology to Pfizer for the development of staphylococcal vaccines.

For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademark of Inhibitex, Inc.

Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024